Analysts Set Medexus Pharmaceuticals Inc. (TSE:MDP) PT at C$5.49

Shares of Medexus Pharmaceuticals Inc. (TSE:MDP) have been assigned a consensus rating of “Buy” from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and four have assigned a strong buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is C$5.49.

A number of brokerages have issued reports on MDP. Ventum Cap Mkts upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 17th. Ventum Financial raised their price objective on shares of Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the company a “buy” rating in a research note on Thursday, January 30th. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Leede Financial upgraded shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, January 22nd. Finally, Stifel Nicolaus lowered shares of Medexus Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price objective for the stock from C$6.00 to C$3.45 in a report on Friday, February 7th.

Medexus Pharmaceuticals Stock Performance

MDP stock opened at C$2.54 on Wednesday. The firm has a 50 day moving average price of C$3.44 and a 200-day moving average price of C$2.91. Medexus Pharmaceuticals has a 52-week low of C$1.47 and a 52-week high of C$5.56. The firm has a market capitalization of C$56.87 million, a price-to-earnings ratio of 12.15 and a beta of 1.96.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.